News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
706,283 Results
Type
Article (41398)
Company Profile (262)
Press Release (664623)
Multimedia
Podcasts (55)
Webinars (12)
Section
Business (205753)
Career Advice (2024)
Deals (35598)
Drug Delivery (99)
Drug Development (81643)
Employer Resources (172)
FDA (16351)
Job Trends (14950)
News (347910)
Policy (33022)
Tag
Academia (2601)
Accelerated approval (5)
Adcomms (21)
Allergies (89)
Alliances (50215)
ALS (94)
Alzheimer's disease (1398)
Antibody-drug conjugate (ADC) (134)
Approvals (16336)
Artificial intelligence (267)
Autoimmune disease (23)
Automation (16)
Bankruptcy (362)
Best Places to Work (11683)
BIOSECURE Act (21)
Biosimilars (112)
Biotechnology (186)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (293)
Cancer (2333)
Cardiovascular disease (180)
Career advice (1691)
Career pathing (30)
CAR-T (155)
Cell therapy (444)
Cervical cancer (20)
Clinical research (66458)
Collaboration (867)
Company closure (2)
Compensation (564)
Complete response letters (21)
COVID-19 (2633)
CRISPR (42)
C-suite (252)
Cystic fibrosis (102)
Data (2305)
Decentralized trials (2)
Denatured (21)
Depression (45)
Diabetes (277)
Diagnostics (6415)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (122)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (99)
Earnings (87174)
Editorial (41)
Employer branding (21)
Employer resources (146)
Events (113459)
Executive appointments (741)
FDA (17726)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (772)
Gene editing (111)
Generative AI (20)
Gene therapy (319)
GLP-1 (727)
Government (4533)
Grass and pollen (4)
Guidances (150)
Healthcare (18910)
Huntington's disease (25)
IgA nephropathy (27)
Immunology and inflammation (128)
Indications (30)
Infectious disease (2780)
Inflammatory bowel disease (147)
Inflation Reduction Act (8)
Influenza (53)
Intellectual property (97)
Interviews (313)
IPO (16590)
IRA (41)
Job creations (3674)
Job search strategy (1436)
Kidney cancer (10)
Labor market (43)
Layoffs (483)
Leadership (17)
Legal (7972)
Liver cancer (77)
Lung cancer (329)
Lymphoma (156)
Machine learning (9)
Management (58)
Manufacturing (331)
MASH (73)
Medical device (13454)
Medtech (13459)
Mergers & acquisitions (19577)
Metabolic disorders (707)
Multiple sclerosis (82)
NASH (16)
Neurodegenerative disease (95)
Neuropsychiatric disorders (27)
Neuroscience (1950)
NextGen: Class of 2025 (6563)
Non-profit (4509)
Now hiring (40)
Obesity (374)
Opinion (212)
Ovarian cancer (80)
Pain (91)
Pancreatic cancer (89)
Parkinson's disease (150)
Partnered (22)
Patents (244)
Patient recruitment (116)
Peanut (49)
People (57746)
Pharmaceutical (65)
Pharmacy benefit managers (19)
Phase I (20735)
Phase II (29246)
Phase III (21808)
Pipeline (1350)
Policy (152)
Postmarket research (2579)
Preclinical (8846)
Press Release (71)
Prostate cancer (107)
Psychedelics (31)
Radiopharmaceuticals (252)
Rare diseases (391)
Real estate (5998)
Recruiting (65)
Regulatory (22679)
Reports (47)
Research institute (2361)
Resumes & cover letters (350)
Rett syndrome (5)
RNA editing (5)
RSV (43)
Schizophrenia (72)
Series A (133)
Series B (88)
Service/supplier (11)
Sickle cell disease (54)
Special edition (16)
Spinal muscular atrophy (149)
Sponsored (30)
Startups (3639)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (49)
The Weekly (32)
Vaccines (724)
Venture capitalists (42)
Weight loss (238)
Women's health (36)
Worklife (16)
Date
Today (43)
Last 7 days (932)
Last 30 days (3063)
Last 365 days (32671)
2025 (11771)
2024 (35503)
2023 (40356)
2022 (51514)
2021 (56054)
2020 (54432)
2019 (46866)
2018 (35316)
2017 (32505)
2016 (31870)
2015 (37942)
2014 (31700)
2013 (26720)
2012 (28898)
2011 (29591)
2010 (27584)
Location
Africa (734)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (38609)
Australia (6284)
California (6397)
Canada (2063)
China (539)
Colorado (273)
Connecticut (279)
Delaware (157)
Europe (83174)
Florida (947)
Georgia (212)
Idaho (57)
Illinois (546)
India (25)
Indiana (320)
Iowa (11)
Japan (171)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (943)
Massachusetts (4782)
Michigan (223)
Minnesota (410)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (67)
New Hampshire (63)
New Jersey (1796)
New Mexico (28)
New York (1803)
North Carolina (992)
North Dakota (9)
Northern California (2807)
Ohio (211)
Oklahoma (14)
Oregon (35)
Pennsylvania (1421)
Puerto Rico (13)
Rhode Island (33)
South America (1116)
South Carolina (25)
South Dakota (1)
Southern California (2413)
Tennessee (105)
Texas (946)
United States (24023)
Utah (190)
Virginia (152)
Washington D.C. (65)
Washington State (563)
West Virginia (3)
Wisconsin (56)
706,283 Results for "affinity biologicals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
REGENXBIO Inc. (Nasdaq: RGNX) today announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE® trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy (Duchenne).
June 24, 2024
·
10 min read
Genetown
AffyImmune Announces Presentation on Affinity-Tuned CAR T Therapy AIC100 at ASCO 2024
AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced an abstract detailing its affinity-tuned CAR T therapy AIC100 will be presented at the American Society of Clinical Oncology 2024 Annual Meeting, held May 31-June 4, at McCormick Place Convention Center in Chicago, IL.
April 24, 2024
·
1 min read
Press Releases
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
April 10, 2025
·
15 min read
Press Releases
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
March 7, 2025
·
6 min read
Press Releases
Specific Biologics Inc. to Present Dualase® Genome Editing for the Precise Removal of Pathogenic Repeats in Repeat Expansion Disorders at the 28th Annual American Society for Gene and Cell Therapy Meeting
May 7, 2025
·
3 min read
Press Releases
MustGrow Signs Exclusive Distribution Agreement with Adjuvants Plus Inc. for Biological Product Line
February 11, 2025
·
8 min read
Policy
Affinity Biosensors Receives FDA Clearance for the LifeScale AST System
Affinity Biosensors, a leading innovator in the field of healthcare diagnostics, announces that its groundbreaking LifeScale AST system has received FDA clearance.
April 3, 2024
·
3 min read
Press Releases
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
December 23, 2024
·
4 min read
Press Releases
Vivex Biologics, Inc. Provides Enrollment Update for its ASCEND Study Examining Whether Supplementing Discs with VIA Disc NP™ Reduces Pain and/or Improves Function in Patients with Symptomatic Disc Degeneration
April 9, 2025
·
2 min read
Genetown
AffyImmune Presents Preclinical Data on AIC100 Affinity-Tuned CAR T Targeting ICAM-1 in Additional Solid Tumor Types at AACR 2024
AffyImmune, a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, presented preclinical data on new indications for its lead program, AIC100, at the American Association for Cancer Research (AACR) Annual Meeting 2024.
April 9, 2024
·
2 min read
1 of 70,629
Next
